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Introduction
The impairment of renal functions can manifest as chronic
kidney disease (CKD) which may end up in end-stage
renal disease (ESRD) with increased morbidity as well as
mortality.1 The National Kidney Foundation classifies CKD
into five stages according to the level of glomerular
filtration rate (GFR).2 The complications associated with
various stages of CKD may be attributed to inflammatory
and oxidative stress observed during the progression of
disease and can be measured by a number of
parameters.3 One of the recently identified markers is
serum ferritin. It is an acute-phase reactant and its level
increases in liver damage and inflammatory states while
its level decreases in iron deficiency anaemia (IDA) and
anaemia of chronic disease (ACD).4
Serum transferrin receptor (sTfR) is another marker which
is a truncated form of the transferrin receptor present on
erythroblasts in bone marrow and many other cells in the
body. Measurement of sTfR is considered better for
reflecting iron metabolism as its levels focus on both body
iron stores and total erythropoiesis.5 The protein sTfR has
been introduced as a promising new diagnostic tool for
differentiating between IDA and ACD as its levels are
proportional to cellular expression of the membrane-
associated transferrin receptor and influenced by
increased cellular iron needs and cellular proliferation.6
As serum ferritin reflects the stored pool of iron and sTfR
reflects the functional iron compartment, the
sTfR/ferritin index (sTfR-F index), has been suggested as
a good estimate of body iron.7 The diagnostic
performance of sTfR, ferritin and sTfR-F index for
detecting iron depletion in several groups of patients
(IDA, chronic inflammation or infection, and non-
haematologic malignancy) has been used.8
The association between inflammation and iron status
has been discovered in early stages of CKD.9 The current
study was planned to explore the relationship of
sTfR:ferritin ratio as an index of iron status and
inflammation in different stages of CKD.
Subjects and Methods
This case-control study was conducted at the Department
of Biological and Biomedical Sciences at the Aga Khan
University Hospital, and Basic Medical Sciences Institute
(BMSI), Jinnah Postgraduate Medical Centre (JPMC),
Karachi, from January to September 2014, and comprised
CKD patients and healthy controls. Patients with liver
disease, cardiovascular disease, acute or chronic
inflammatory disease and those who were on steroid
therapy were excluded.  Group 1 comprised controls,
whereas groups 2, 3 and 4 had CKD patients based on
their mean GFR values.
After, the study was approved by the BSMI review board,
and informed consent was obtained from all the
participants, baseline demographic and clinical data was
obtained from medical records and interviews with
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patients at enrolment. All the participants were requested
to come with 10-12 hours of fasting for sample collection.
The analysis of biochemical parameter, including urea and
creatinine, was done by commercially available kits (Cat #
5.17610.0001; Merck France). GFR was estimated in line
with literature.9 Serum Iron was analysed by enzymatic
colorimetric method (Cat # 61075 BioMerieux, France)
(reference range: male: 0.65-1.70 mg/dl; female: 0.5-1.70
mg/dl). Serum ferritin (Cat # BC- 1025; BioCheck, United
States) (reference range: male: 28-365 ng/dl; female: 5-148
ng/dl) and soluble transferrin receptor (Cat # YHB2785Hu,
YH Bioresearch China) (reference range: male: 2.2-5.0
mg/L; female: 1.9-4.4 mg/L) were measured by
commercially available enzyme-linked immunosorbent
assay (ELISA) kits method.
SPSS 19 was used for data analysis. Data on continuous
variables, i.e. biophysical (age, height, weight, body mass
index [BMI], blood pressure, etc.) and biochemical (serum
cholesterol, triglycerides, high-density lipoprotein
cholesterol [HDL-C[, urea, creatinine, etc.) parameters, was
calculated as mean ± standard deviation (SD). Statistical
comparisons were computed using Mann-Whitney U test
for continuous/quantitative variables. Pearson's
correlation (r) was used to determine the correlation
between GFR levels and lipid profile. P<0.05 was
considered significant.
Results
Of the 170 participants, 126(74.1%) were patients and
44(25.9%) were controls. Group 1 comprising controls had
mean GFR of 116±8.3. Groups 2, 3 and 4 had 42(33%)
patients each, with mean GFR values of 79± 5.2, 45±2.5
and 20.22±8.5 respectively. The overall mean age and the
mean BMI was 55.87±3.48 years and 24.25±2.9kg/m2,
respectively. The mean iron level was 2.50±1.16 mg/dl in
group 1, 1.80±0.24 in group 2, 1.04±0.24 in group 3 and
0.22±0.15 in group 4 (p<0.001), whereas haemoglobin
level was 13.33±1.78 gm /dl, 11.87±2.41, 10.06±2.41 and
7.89±2.16, respectively (p<0.001). Serum ferritin level was
4.72±1.71 in controls compared to 32.17±9.19,
57.90±12.84 and 89±8.77 in groups 2, 3 and 4,
respectively (p<0.001). The sTfR/F ratio was 1.68±0.61 in
group 1, 0.34±0.18 in group 2, 0.24±0.13 in group 3 and
0.18±0.05 in group 4 (p<0.001) (Table). 
Discussion
Serum ferritin levels in our study increased with reduction
in GFR; this finding was comparable to other
researchers.10 The increase can be attributed to non-
specific protein synthesis for compensation of protein loss
in advanced CKD. The results can be compared with
Gupta et al., who observed high serum ferritin levels in
CKD patients as compared to controls.6,11 This can be
explained on the basis of increased ferritin expression
with progression of inflammation in CKD patients.  
Serum transferrin receptor levels have been used as a
better indicator of iron deficiency, as it helps in
diagnosing coexistent iron deficiency in anaemia of
chronic disorders as is uninfluenced by the degree of
inflammation.4 Thus,  sTfR is expected to be a better
clinical measure of iron status in inflammatory conditions
as it is  neither effected by erythropoiesis nor
inflammation.12 It also helps in monitoring extent of
erythropoiesis.6 The increased sTfR in our study explains
decreased intracellular iron which tends to increase iron
absorption.13 The decreased iron levels with increased
J Pak Med Assoc
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Table: Biophysical & Biochemical Parameters of the study subjects.
Variable Group I (Control) Group II (CKD) Group III (CKD) Group IV (CKD) p value
(n= 44) Mean ± SD (n = 42) Mean ± SD (n = 42) Mean ± SD (n = 42) Mean ± SD
Age (years) 55.73 ± 2.47 54.78±2.54 55.42±3.42 57.56 ±5.49 >0.5
Weight (kg) 58.7 ± 2.47 62.9±9.7 68.311±9.54 64.9 ± 9.7 <0.5
BMI(kg/m2) 23.6 ±2.03 22.9±2.56 24.51±3.56 26 ±3.42 >0.5
GFR 116 ± 8.3 79± 5.2 45± 2.5 20.22 ± 8.5 <0.001
Haemoglobin (gm/dl) 13.33±1.78 11.87±2.41 10.06±2.41 7.89±2.16 <0.001
Iron (mg/dl) 2.50±1.16 1.80±0.24 1.04±0.24 0.22±0.15 <0.001
Ferritin (ng/dl) 4.72±1.71 32.17±9.19 57.90±12.84 89±8.77 <0.001
Transferrin receptor  (mg/dl) 7.31±1.81 10.13±2.58 13±4.12 15.93±3.58 <0.001
sTfR/Ferritin ratio 1.68±0.61 0.34±0.18 0.24±0.13 0.18±0.05 <0.001
Data is presented as Mean ± S.D. Man-Whitney U test was applied to compare groups. P value of <0.05 was considered significant.
CKD: Chronic kidney disease
BMI: Body mass index
GFR: Glomerular filtration rate
sTfR: Serum transferrin receptor
SD: Standard deviation.
ferritin are also reported in our previous study.14 and
another study by our group suggests sTfR to be a better
marker for iron demand in the body.
All the researchers have agreed that ferritin is sensitive to
excessive body iron stores and inflammation. On the
contrary, sTfR reflects the degree of the tissue iron supply
and is not influenced by acute or chronic inflammation.
Because of this complementary relationship between
these 2 indices with respect to measurements of body
iron stores, the sTfR-ferritin ratio was suggested to be a
better marker than ferritin to measure a wide range of iron
status.15,16
Therefore, evaluation of iron status in patients with
chronic disease requires different serum ferritin cut-offs
according to diagnostic classification, and the sTfR-F
index adds information on patients with chronic
inflammation or infection. Several researchers have
employed sTfR/ log ferritin ratio, sTfR-F index as the tool
for the diagnosis of iron deficiency anaemia and a cut-off
value of >1.85 has been determined.17 In another study,
the mean index was >1.4, indicating iron deficiency
anaemia co-existing with anaemia of chronic disease;
however, index up to 1.3 shows merely an anaemia of
chronic disease.6 There are a few prospective studies
which have investigated the associations of the sTfR-
ferritin ratio with coronary heart disease (CHD). In a small
case-control study conducted in Finland, a lower sTfR-
ferritin ratio was associated with an elevated risk of CHD;15
but this association was not present in another
retrospective case-control study.18We observed that sTfR-
ferritin ratio had a positive correlation with GFR. 
It is important to assess iron stores to assess the status
and risk of premature acute myocardial infarction. In the
progression of CKD, cardiovascular events are the major
cause of death.19 Functional iron deficiency at the same
time develops during treatment with recombinant
human erythropoietin and in the infectious state and
during the inflammatory process.19 The measurement of
iron stores at this moment can give an insight to the
status of kidney functions in CKD patients. Our study
involved different stages of CKD patients, and thus the
mean age of the four groups was not comparable. The BMI
of the four groups was significantly different, but a recent
study shows that change in BMI does not reflect the
progress of CKD as it is a vague parameter to judge the
nutritional status as well as the body composition in such
a disease. The increased BMI in our study groups could be
due to water retention as these patients were not yet
receiving dialysis treatment.20
Our study, however, reveals a decline in haemoglobin as
well as iron levels across the four groups. Stancu et al.
showed a similar decrease in haemoglobin levels in CKD
patients.21 This could be due to the decreased intestinal
iron absorption which is subsequent to increased ferritin
concentration in the diseased patients. This is consistent
with the reports of the previous study.22The association of
ratio of sTfR-ferritin with  the risk of acute myocardial
infarction and  anaemia due to chronic inflammation in
inflammatory bowel disease has been documented by
researchers.23,24 We have emphasised broader scope of
the sTfR-ferritin ratio with renal functions of CKD,
nonetheless all integral components involved in
progression of CKD need to be further expanded and
validated with the recruitment of more patients from
other nephrology units in subsequent studies.
Conclusion
The sTfR-ferritin ratio was lower in higher stages of CKD.
Therefore, the ratio may be used as an index of
measurement of renal function in CKD.
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